Pancreatic cancer is the most difficult cancer in the world with an overall five-year survival rate of just 11%. It is currently the third leading cause of cancer-related death in the United States, underscoring the urgent need for new treatment options and research findings in this area. PanCAN’s Precision Promise, launched in 2020, strives to revolutionize the clinical development paradigm for this disease by enabling a faster, more efficient and patient-centric approach to developing new treatment options and improving outcomes for patients with pancreatic cancer.

PanCAN’s new clinical trial is testing the effectiveness of experimental pancreatic cancer therapies – including this new drug combination from Novartis – more efficiently by requiring fewer patients to understand if a potential new therapy works. Through Precision Promise, Novartis will test canakinumab (IL-1 beta inhibitor) and spartalizumab (PD-1 inhibitor) in combination with nab-paclitaxel and gemcitabine. This new combination therapy will be made available to patients through Precision Promise as each clinical trial site fully activates the new protocol. Interested patients should inquire with their physician regarding availability at their local site.

“The adaptive nature of Precision Promise allows us to regularly bring innovative investigational therapies to study against the current standard of care and we are excited to bring an investigational treatment option from Novartis into the fold,” said Julie FleshmanJD, MBAPresident and CEO of PanCAN.

In addition to integrating Novartis’ investigational treatment into the study, PanCAN announced the addition of five new sites to the fifteen already active sites where pancreatic cancer patients will be able to access the trial. New designated sites include:

  • Harold C. Simmons Cancer Center (Dallas, TX)
  • Huntsman Cancer Institute at University of Utah (Salt Lake City, UT)
  • Mayo Clinic Cancer Center (Rochester, Minnesota.)
  • Sylvester Cancer Center (Miami, Florida.)
  • University of Michigan Rogel Cancer Center (Ann Arbour, Mich.)

Following the activation of these five additional institutions, PanCAN also plans to add 10 additional sites by early 2023, bringing Precision Promise to a total of 30 leading cancer centers nationwide and doubling the footprint of the test. A full list of institutions currently open and actively recruiting patients is available at This list is updated as new sites are activated.

“Patients with pancreatic cancer deserve better treatment options,” said Fleshman, “We hope that by expanding Precision Promise’s access to more diverse populations and thirty sites in total by the early in 2023, we will be able to deliver results that will improve patient outcomes in the future.”

When selecting new sites for its Precision Promise clinical trial, PanCAN evaluated not only facilities with strong pancreatic cancer programs, but also facilities in different geographic regions that serve a diverse patient population in order to Expand access to testing to typically underserved communities.

For more information on Precision Promise and PanCAN’s commitment to research in its urgent mission to save lives, visit or follow PanCAN on Twitter, instagram and Facebook.

About the Pancreatic Cancer Action Network
The Pancreatic Cancer Action Network (PanCAN) is leading the way in accelerating critical progress for patients with pancreatic cancer. PanCAN is taking bold steps by funding lifesaving research, providing personalized patient services, and building a community of supporters and volunteers who will stop at nothing to create a world in which all pancreatic cancer patients will thrive.

Media Contact:
Jillian Scholten
Senior Manager, Public Relations
Pancreatic Cancer Action Network
Direct: 310-706-3360
E-mail: [email protected]

SOURCE Pancreatic Cancer Action Network

Comments are closed.